Inception | $50,000,000 | (Nov 7, 2025)
SiteLabs | $2,000,000 | (Nov 7, 2025)
DealMaker | $20,000,000 | (Nov 7, 2025)
Certified by Founder
Lodge
NeuroSense Therapeutics
start up
United States
- Cambridge, Massachusetts
- 09/12/2021
- Unknown
- $12,000,000
Advancing research, development and therapy for ALS and additional CNS indications.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical stage Biotech company focusing on the development of a ground-breaking treatment for ALS patients, as well as other neurodegenerative diseases.
Currently in preparations towards a Phase IIb in ALS patients in USA and Israel.
- Industry Biotechnology Research
- Website http://www.neurosense-tx.com/
- LinkedIn https://www.linkedin.com/company/neurosense-therapeutics/about/
Related People
Alon Ben-NoonCo Founder
Israel -
Herzliyya, Tel Aviv
Life Sciences Executive ; Leading NeuroSense Therapeutics, a Biotech startup which accelerates research, development and therapy for ALS (Amyotrophic Lateral Sclerosis) and additional Neurodegenerative diseases.
LinkedIn
https://www.linkedin.com/in/alonbn/
Flint(US) | $15,000,000 | (Nov 7, 2025)
Subtle Computing | $6,000,000 | (Nov 7, 2025)
IndustrialMind.ai | $1,200,000 | (Nov 7, 2025)
Fintary | $10,000,000 | (Nov 7, 2025)
Graymatter Labs | $1,300,000 | (Nov 7, 2025)
Avallon AI (YC X25) | $4,600,000 | (Nov 7, 2025)
Kaizen Labs | $12,000,000 | (Nov 7, 2025)
Giga | $61,000,000 | (Nov 7, 2025)
Reevo | $80,000,000 | (Nov 7, 2025)